Morgan Stanley has maintained its overweight call on Apollo Hospitals with a target price of ₹8,050 per share, reflecting a positive outlook on the company’s continued growth momentum. The brokerage said consolidated revenue was in line with estimates, supported by healthy performance across healthcare services, Apollo HealthCo, and Apollo Health & Lifestyle Ltd (AHLL).
Consolidated EBITDA rose 15% year-on-year, in line with projections, with margins steady at 14.9%. Morgan Stanley also highlighted that the company’s 24/7 business losses narrowed both sequentially and annually—down 3% quarter-on-quarter and 22% year-on-year. Profit after tax for the quarter came in above estimates, indicating improved operational efficiency and strong execution across verticals.
At the time of the report, Apollo Hospitals shares were trading at ₹7,783.
Disclaimer: The views and target price mentioned are those of the brokerage firm (Morgan Stanley). This article is based solely on the provided inputs and is intended for informational purposes only. No investment advice.
